US 12,065,508 B2
Multispecific antigen-binding molecules for cell targeting and uses thereof
Lauric Haber, Rye Brook, NY (US); Jennifer A. Finney, Park Ridge, NJ (US); Ryan McKay, Peekskill, NY (US); Eric Smith, New York, NY (US); and Chia-Yang Lin, Scarsdale, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Apr. 8, 2022, as Appl. No. 17/716,830.
Application 17/716,830 is a continuation of application No. 16/993,721, filed on Aug. 14, 2020.
Claims priority of provisional application 63/057,824, filed on Jul. 28, 2020.
Claims priority of provisional application 62/978,584, filed on Feb. 19, 2020.
Claims priority of provisional application 62/924,435, filed on Oct. 22, 2019.
Claims priority of provisional application 62/887,411, filed on Aug. 15, 2019.
Prior Publication US 2022/0251244 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/468 (2013.01) [C07K 14/7051 (2013.01); C07K 14/70539 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01)] 25 Claims
 
1. A method of treating cancer, comprising administering to a subject in need thereof, a multispecific antigen-binding molecule, comprising:
(a) a first polypeptide comprising, from N-terminus to C-terminus (i) a first antigen-binding domain that specifically binds human CD3, wherein the first antigen-binding domain comprises an immunoglobulin Fab domain comprising a heavy chain variable region (HCVR) and a heavy chain CH1 domain paired with a light chain variable region (LCVR) and a light chain CL domain; (ii) a first multimerizing domain comprising an immunoglobulin Fc domain; and (iii) a second antigen-binding domain that specifically binds human CD3, wherein the second antigen-binding domain is a single chain variable fragment (scFv) domain comprising a HCVR and a LCVR connected by a peptide linker; and
(b) a second polypeptide comprising, from N-terminus to C-terminus (i) a third antigen-binding domain that specifically binds a tumor-associated antigen, wherein the third antigen-binding domain comprises an immunoglobulin Fab domain comprising a HCVR and a heavy chain CH1 domain paired with a LCVR and a light chain CL domain; (ii) a second multimerizing domain comprising an immunoglobulin Fc domain; and (iii) a fourth antigen-binding domain that specifically binds a tumor-associated antigen, wherein the fourth antigen-binding domain is a scFv domain comprising a HCVR and a LCVR connected by a peptide linker,
wherein the first and the second multimerizing domains associate with one another to form the molecule.